Shandong Jincheng Pharmaceutical Group Co., Ltd

Equities

300233

CNE100001500

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
16.21 CNY +3.78% Intraday chart for Shandong Jincheng Pharmaceutical Group Co., Ltd +6.57% -2.70%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for the Year 2023 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Shandong Jincheng Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on February 2, 2024. CI
Shandong Jincheng Pharmaceutical Group Co., Ltd's Equity Buyback announced on February 2, 2024, has closed with 4,543,000 shares, representing 1.18% for CNY 55 million. CI
Shandong Jincheng Pharmaceutical Group Co., Ltd announces an Equity Buyback for CNY 70 million worth of its shares. CI
Shandong Jincheng Pharmaceutical Group Co., Ltd authorizes a Buyback Plan. CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Jincheng Pharmaceutical Gets License to Produce E-Cigarette Nicotine MT
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Approves Directorate Appointments CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Approves Cash Dividend for the Year 2022 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for 2022 CI
Three Jincheng Pharmaceutical Medicines Shortlisted For China’s Drug Procurement Program MT
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Jincheng Pharma Secures China's First License to Produce E-Cigarettes; Shares Slide 5% MT
Shandong Jincheng Pharmaceutical Group Co., Ltd Announces Final Profit Distribution Plan for 2021, Payable on May 11, 2022 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Approves Profit Distribution for the Year 2021 CI
Shandong Jincheng Pharma Maintains Final Dividend After Swinging to Profit in 2021 MT
Shandong Jincheng Pharmaceutical Group Co., Ltd Announces the Profit Distribution Proposal for the Year 2021 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Chart Shandong Jincheng Pharmaceutical Group Co., Ltd
More charts
Shandong Jincheng Pharmaceutical Group Co., Ltd., formerly Shandong Jincheng Pharmaceutical Co., Ltd., is a China-based company principally engaged in the research, development, production and sale of cephems medicine intermediates. The Company mainly provides active ester side chain of cephalosporin products, other pharmaceutical chemical products, as well as bio-pharmaceuticals and specialty active pharmaceutical ingredient (API). The Company distributes its products within domestic market and to overseas markets.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300233 Stock
  4. News Shandong Jincheng Pharmaceutical Group Co., Ltd
  5. Shandong Jincheng Pharmaceutical : Pharma Buys Back More Shares; Shares Slide Nearly 3%